Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035600 | 0.81 | OPRK1 (0.49) | DRD2HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL24170260 | 0.81 | DRD2 (0.65) | KDM4EALDH1A1LMNAMAPTDRD2 | |
| SCHEMBL13648739 | 0.80 | DRD2 (0.65) | DRD2HTR2ADRD4HTR2CHTR1A | |
| SCHEMBL1813295 | 0.79 | MAPT (0.67) | KDM4EALDH1A1LMNAMAPTDRD2 | |
| Ammonia Solution, Strong SCHEMBL2320933 | 0.79 | DRD2 (0.64) | DRD2HTR2ADRD4HTR2CHTR1A | |
| SCHEMBL6355490 | 0.79 | ALDH1A1 (0.60) | KDM4EALDH1A1LMNAMAPTDRD2 | |
| SCHEMBL1397389 | 0.78 | DRD2 (0.60) | HTR4KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL13698528 | 0.78 | DRD2 (0.59) | KDM4EALDH1A1LMNAMAPTDRD2 | |
| SCHEMBL14320628 | 0.78 | MAPT (0.59) | KDM4EALDH1A1LMNAMAPTDRD2 | |
| SCHEMBL7031376 | 0.77 | DRD4 (0.60) | KDM4EALDH1A1LMNADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | claimed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | ACHE 5/4885HTR4 1360/4885KDM4E 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.